Related Experiment Video
Updated: May 21, 2026

Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells
Published on: June 28, 2013
High-purity enrichment of functional cardiovascular cells from human iPS cells
1Department of Developmental Biology, University of Pittsburgh School of Medicine, 530 45th Street, Rangos Research Center, Pittsburgh, PA 15201, USA.
Insights
Researchers developed a method to generate pure human cardiovascular cells from induced pluripotent stem cells (iPSCs). This advance aids in studying inherited heart diseases and developing new cardiac cell therapies.
Area of Science:
- Cardiovascular Biology
- Stem Cell Research
- Regenerative Medicine
Background:
- Inherited heart diseases impact cardiomyocytes, endothelial cells, and smooth muscle cells.
- Efficient production of cardiac cell lineages from human stem cells is crucial for research and therapy.
Purpose of the Study:
- Develop a reproducible method to generate pure cardiovascular cell types from human induced pluripotent stem cells (iPSCs).
- Enable the study of human inherited heart diseases and the development of cardiac cell therapeutics.
Main Methods:
- Generated human multipotent cardiovascular progenitor cells from iPSCs.
- Selectively differentiated progenitor cells into cardiomyocytes (CMs), endothelial cells (ECs), and smooth muscle cells (SMCs).
- Utilized fluorescence-activated cell sorting for high-purity enrichment (>90%) of each cell type.
Main Results:
- Enriched cardiovascular cells displayed specific gene expression and normal in vitro/in vivo functions.
- Cardiomyocytes from LEOPARD syndrome patient iPSCs showed expected gene expression related to cardiac hypertrophy.
- Successfully generated a renewable resource of pure human cardiovascular cells.
Conclusions:
- This method provides a valuable source of pure human cardiovascular cells for disease mechanism studies.
- Facilitates the development of future drug and cell-based therapeutics for heart disease.
- Enables detailed investigation into inherited cardiac conditions using patient-specific iPSC-derived cells.
Aims:
A variety of human inherited heart diseases affect the normal functions of cardiomyocytes (CMs), endothelial cells (ECs), or smooth muscle cells (SMCs). To study human heart disease and generate cardiac cells for basic and translational research, an efficient strategy is needed for production of cardiac lineages from human stem cells. In the present study, a highly reproducible method was developed that can simultaneously enrich a large number of CMs and cardiac SMCs and ECs from human induced pluripotent stem (iPS) cells with high purity.
Methods And Results:
Human multipotent cardiovascular progenitor cells were generated from human iPS cells, followed by selective differentiation of the multipotent cardiovascular progenitor cells into CMs, ECs, and SMCs. With further fluorescence-activated cell sorting, each of the three cardiovascular cell types could be enriched with high purity (>90%). These enriched cardiovascular cells exhibited specific gene expression signatures and normal functions when assayed both in vitro and in vivo. Moreover, CMs purified from iPS cells derived from a patient with LEOPARD syndrome, a disease characterized by cardiac hypertrophy, showed the expected up-regulated expression of genes associated with cardiac hypertrophy.
Conclusions:
Overall, our technical advance provides the means for generating a renewable resource of pure human cardiovascular cells that can be used to dissect the mechanisms of human inherited heart disease and for the future development of drug and cell therapeutics for heart disease.
More Related Videos
11:53Derivation of Highly Purified Cardiomyocytes from Human Induced Pluripotent Stem Cells Using Small Molecule-modulated Differentiation and Subsequent Glucose Starvation
Published on: March 18, 2015
08:06Generation of Ventricular-Like HiPSC-Derived Cardiomyocytes and High-Quality Cell Preparations for Calcium Handling Characterization
Published on: January 17, 2020